Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2019.04.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol
December 2024
Labcorp, Durham, NC, USA; Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Background: Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and survival outcomes. MIRV targets folate receptor alpha (FRα), a cell-surface receptor that is overexpressed in EOC and has been associated with aggressive disease phenotypes.
View Article and Find Full Text PDFThe discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer.
Sci Rep
October 2024
Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
The somatic BRCA1 or BRCA2 Pathogenic Variant (PV)/Likely PV (LPV) from Next Generation Sequencing (NGS) is the most important biomarker for PARP inhibitor use and maintenance-targeted therapies. A discrepancy in the detection rates of BRCA1 and BRCA2 PV/LPV was identified among the NGS platforms. The objective of this study was to compare the somatic BRCA results from two distinct platforms using the same cohort and to identify the causes of these differences.
View Article and Find Full Text PDFAssessing pathogenicity of mismatch repair variants of uncertain significance by molecular tumor analysis.
Exp Mol Pathol
December 2024
Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands. Electronic address:
Functional analyses are the main method to classify mismatch repair (MMR) gene variants of uncertain significance (VUSs). However, the pathogenicity remains unclear for many variants because of conflicting results between clinical, molecular, and functional data. In this study, we evaluated whether whole exome sequencing (WES) could add another layer of evidence to elucidate the pathogenicity of MMR variants with conflicting interpretations.
View Article and Find Full Text PDFReliability, reproducibility, and potential pitfalls of the O-RADS scoring with non-dynamic MRI.
Acta Radiol
December 2024
Radiology Department, T.C. Ministry of Health, Ankara Bilkent City Hospital, Ankara, Türkiye.
Article Synopsis
- The O-RADS scoring system aims to standardize the reporting of adnexal lesions detected via non-dynamic MRI to enhance diagnosis accuracy.
- A study assessed the consistency between different observers (intra- and inter-observer agreement) using kappa statistics, revealing strong agreements and a high level of accuracy in distinguishing between benign and borderline/malignant lesions.
- The findings support O-RADS as a reliable tool for identifying potentially dangerous lesions, with additional insights into factors that cause rating discrepancies among observers.
Application of Differential Subsampling with Cartesian Ordering in Evaluating Left Ovarian Venous Reflux for Pretreatment Planning for Pelvic Venous Disorders.
Diagnostics (Basel)
August 2024
Department of Radiology, University of California San Diego, La Jolla, CA 92093, USA.
The diagnosis of a common cause of chronic pelvic pain can be made by visualizing reflux in the ovarian veins. Fluoroscopic venography is the gold standard for diagnosing ovarian vein reflux, but it is an invasive technique that exposes patients to ionizing radiation. MRI, with its lack of ionizing radiation and capability of high-temporal and spatial-resolution vascular imaging, has the potential to provide similar diagnostic information.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!